The company's interdisciplinary team of scientists, physicians, and innovators collaborate to develop FDA-approved therapeutics for Bronchopulmonary Dysplasia (BPD), Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF), and Pulmonary Arterial Hypertension (PAH) using microbiome-based pathways and drug delivery modalities. Their clinical pipeline includes preclinical phase live biotherapeutics for these lung diseases.